News & Media

Press releases & statements

Apply filter
Sep 12, 2023
Statement
COVID-19

U.S. CDC and Advisory Committee Recommend Use of Authorized and Approved 2023-2024 Monovalent XBB COVID-19 Vaccines

Read full article
Download
Aug 22, 2023
COVID-19

Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6

Read full article
Download
Jul 13, 2023
Statement
COVID-19

Novavax Intends to Deliver Protein-based XBB COVID Vaccine as Specified in U.S. HHS Letter to COVID Manufacturers

Read full article
Download
Jul 6, 2023
COVID-19

Novavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the Prevention of COVID

Read full article
Download
Jun 15, 2023
COVID-19

Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall

Read full article
Download
May 26, 2023
COVID-19

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

Read full article
Download
May 12, 2023
COVID-19

Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore

Read full article
Download
May 9, 2023
COVID-19,Seasonal influenza

Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses

Read full article
Download
Apr 4, 2023
COVID-19,Seasonal influenza

Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases

Read full article
Download
Feb 13, 2023
COVID-19

U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine

Read full article
Download
Showper page